 |
|
|
|
 |
|
|
| Article 1 to 8 out of 8 concerning Novo Nordisk A/S
|
-
Merrion Pharmaceuticals plc Announces Commencement of Next Stage of Oral Drug Research Collaboration Programme With Novo Nordisk
(22 Jul 2008)
Merrion Pharmaceuticals today announced the continuation of an oral drug delivery research collaboration programme with Novo Nordisk. This follows on from the completion of several oral feasibility studies combining Merrion's Gastrointestinal ...
-
Novo Nordisk Appoints Alan C. Moses as Chief Medical Officer Worldwide
(11 Jan 2008)
Novo Nordisk announced the appointment of Alan C. Moses, M.D. as vice president, chief medical officer worldwide. Moses is currently the chief medical officer of Novo Nordisk Inc., the company's U.S. affiliate.In the newly expanded role, Moses will ...
-
Millipore and Novo Nordisk Expand Agreement to Supply Biopharmaceutical Market with Recombinant Human Insulin
(17 Aug 2007)
Millipore gains long-term exclusive worldwide rights to distribute Novo Nordisk's insulin for cell culture applications
Millipore Corporation announced an expansion of its agreement with Novo Nordisk to provide the biopharmaceutical market with recombinant human insulin, a key cell culture supplement used to manufacture biologic drugs. Under the terms of the ...
-
Novo Nordisk and Sangamo BioSciences Announce Agreement
(12 Sep 2005)
Novo Nordisk A/S and Sangamo BioSciences, Inc. announced an agreement that provides Novo Nordisk with access to Sangamo's proprietary zinc finger DNA-binding protein (ZFP) technology. Sangamo will provide its ZFP technology for Novo Nordisk to ...
-
Novo Nordisk strengthens drug research - creates dedicated biopharmaceuticals research unit
(17 Aug 2005)
With the purpose of boosting innovation and building a broader presence within biopharmaceuticals, Novo Nordisk has reorganised its drug research organisation. The reorganisation creates two new research units - one devoted to diabetes and one to ...
-
A-Bio Secures Major Deal with Novo Nordisk
(01 Jun 2005)
A-Bio Pharma Pte Ltd (A-Bio) announced that it has entered into a multi-year Master Service Agreement with Novo Nordisk A/S. Under the agreement, Novo Nordisk will engage A-Bio for process development and GMP clinical supply of biologics in its ...
-
MIP Technologies and FeF Chemicals sign Research and Development Agreement
(25 Jan 2005)
MIP Technologies AB, a developer of molecular molecularly imprinted polymers for separations and drug discovery, announced that it has signed a research and development agreement with FeF Chemicals, a subsidiary of Novo Nordisk. During this program ...
-
Morphotek and Novo Nordisk to collaborate in developing High-Titer Cell Lines for Manufacturing of Therapeutic Antibodies
(03 Dec 2004)
Morphotek, Inc. has entered into a multi-product Research Collaboration and License Agreement with Novo Nordisk for the use of Morphotek's proprietary MORPHODOMA(R) technology to develop high-affinity antibodies and high-titer antibody-producing ...
Additional information
Novo Nordisk A/S
Bagsværd, Denmark
Company
|
|
|
|
|
|
Top
